AVLN
Avalyn Pharma Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.28B
P/E Ratio
—
EPS
$-2.04
Beta
—
52W High
$32.23
52W Low
$25.05
50-Day MA
$28.74
200-Day MA
$28.74
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with severe respiratory diseases. Its lead product candidate, AV-101, is designed to address the unmet medical needs in pulmonary diseases by targeting the underlying mechanisms of lung inflammation and fibrosis. With a robust pipeline and a commitment to advancing next-generation treatments, Avalyn is strategically positioned to capitalize on the growing demand for effective respiratory therapies. The company's experienced leadership team and scientific advisory board underscore its potential to drive significant advancements in patient outcomes within the respiratory health sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-91.25M |
| Operating Margin | 0.00% |
| Return on Equity | -68.30% |
| Return on Assets | -41.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-10.11 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $44.31M |
| Float | $14.45M |
| % Insiders | 0.00% |
| % Institutions | 52.92% |
More HEALTHCARE Stocks
Data last updated: 5/25/2026